Loading...
Loading...
AURA| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.3M |
| Gross Profit | -0.3M |
| Operating Expense | 22.4M |
| Operating I/L | -22.8M |
| Other Income/Expense | 2.4M |
| Interest Income | 2.5M |
| Pretax | -20.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -20.3M |
Aura Biosciences, Inc. is a biotechnology company specializing in the development of virus-like drug conjugates (VDC) for the treatment of high unmet need tumors in ocular and urologic oncology. Their lead candidate, AU-011, is designed to treat primary choroidal melanoma and other ocular oncology indications, including choroidal metastases. By leveraging their innovative VDC technology platform, the company aims to provide effective therapies for cancer patients. Through the development and commercialization of these novel treatments, Aura Biosciences generates revenue from the sale of their proprietary therapies and potential licensing agreements.
